Indeed, a large number of studies, including ours, have revealed that HDAC inhibitors, such as TSA, SAHA, and VPA, significantly enhance the cytotoxicity of cisplatin against a variety of cancers in vitro and in vivo. This evidence concerns the gene HDAC9 and cancer.